GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Onconova Therapeutics ONTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

6.38

+24.61%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

$226,000

FY2014FY2023

Net income

−$18.9m

FY2014FY2023

Free cash flow

−$17.9m

FY2014FY2023

Shareholders' equity

$10.7m

FY2014FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$226,000$226,000$226,000$230,000$2.2m$1.2m$790,000$5.5m$11.5m$800,000
Research and development$11.4m$11.4m$7.3m$16.9m$15.5m$16.9m$19.1m$20.1m$25.9m$49.4m
Operating income−$20.3m−$19.6m−$16.5m−$25.0m−$21.7m−$23.3m−$25.7m−$23.7m−$24.0m−$63.7m
Net income−$18.9m−$19.0m−$16.2m−$25.2m−$21.5m−$20.6m−$24.1m−$19.7m−$24.0m−$63.7m
Diluted earnings per share-0.90-0.91-0.96-2.17-22.39-76.18-602.25-983.50-2,398.00-6,368.00

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$22.7m$39.4m$55.5m$20.0m$23.7m$17.9m$5.0m$23.2m$23.4m$47.3m
Cash and short-term investments$20.8m$38.8m$55.1m$19.0m$22.7m$17.0m$4.0m$21.4m$19.8m$43.6m
Total liabilities$12.0m$11.1m$9.4m$13.8m$12.1m$12.5m$16.7m$18.9m$13.4m$24.6m
Shareholders' equity$10.7m$28.3m$46.1m$6.2m$11.6m$5.4m−$11.7m$4.3m$10.0m$22.7m
Shares outstanding21m21m17m12m1m0m0m0m0m0m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$17.9m−$16.3m−$19.5m−$23.1m−$20.8m−$22.7m−$23.8m−$15.8m−$31.2m−$57.6m
Capital spending−$14,000——−$20,000−$60,000————−$230,000
Free cash flow−$17.9m−$16.3m−$19.5m−$23.1m−$20.9m−$22.7m−$23.8m−$15.8m−$31.2m−$57.9m

Latest quarters

By quarter end

Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022
Revenue$56,000$57,000$57,000$60,000$60,000$60,000$60,000$60,000
Gross profit—$57,000——————
Operating income−$4.5m−$5.1m−$4.6m−$6.1m−$5.7m−$5.6m−$4.1m−$4.1m
Net income−$4.2m−$4.7m−$4.3m−$5.8m−$5.4m−$5.4m−$4.0m−$4.1m
Diluted earnings per share-0.20-0.23-0.20-0.28-0.26-0.26-0.19-0.20
Total assets$22.7m$27.0m$30.5m$35.1m$39.4m$43.8m$48.1m$51.4m
Cash and short-term investments$20.8m$25.2m$29.7m$34.2m$38.8m$42.6m$46.5m$50.8m
Shareholders' equity$10.7m$14.5m$18.9m$22.9m$28.3m$33.4m$38.5m$42.3m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-0.6%-28.7%-26.3%
Operating income-6.7%-2.7%-10.6%
Net income-9.0%-1.6%-11.6%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-8833.0%-8966.0%-2927.1%-1177.4%
Net margin-8387.6%-8726.3%-2809.3%-1147.8%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 25-to-1 reverse split · 23 Sept 2024
  • 15-to-1 reverse split · 21 May 2021
  • 15-to-1 reverse split · 26 Sept 2018
  • 10-to-1 reverse split · 1 Jun 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.